Resistance to polymyxins: Mechanisms, frequency and treatment options

Drug Resistance Updates

Volumn 13, Issue 4-5, 2010, Pages 132-138

  Falagas, Matthew E ^a,b,c   Rafailidis, Petros I ^a,b   Matthaiou, Dimitrios K ^a,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Colistin; Fosfomycin; Multidrug resistance; Pandrug resistance; Polymyxin; Tigecycline

Indexed keywords

AMPICILLIN; COLISTIN; FOSFOMYCIN; MEROPENEM; POLYMYXIN A; POLYMYXIN B; POLYMYXIN D1; POLYMYXIN DERIVATIVE; POLYMYXIN NONAPEPTIDE; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; DRUG MECHANISM; HUMAN; KLEBSIELLA INFECTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTERNATIONALITY; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; POLYMYXINS; TRANSCRIPTION FACTORS;

EID: 77957951965     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.05.002     Document Type: Article

References (97)

1. Adams M.D., Nickel G.C., Bajaksouzian S., Lavender H., Murthy A.R., Jacobs M.R., Bonomo R.A. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 2009, 53:3628-3634.
2. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect Dis. 2008, 46:567-570.
3. Bell A., Hancock R.E. Outer membrane protein H1 of Pseudomonas aeruginosa: purification of the protein and cloning and nucleotide sequence of the gene. J. Bacteriol. 1989, 171:3211-3217.
4. Bengoechea J.A., Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol. Microbiol. 2000, 37:67-80.
5. Bratu S., Mooty M., Nichani S., Landman D., Gullans C., Pettinato B., Karumudi U., Tolaney P., Quale J. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 2005, 49:3018-3020.
6. Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 2005, 56:128-132.
7. Breazeale S.D., Ribeiro A.A., McClerren A.L., Raetz C.R. A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-amino-4-deoxy-l-arabinose. Identification and function of UDP-4-deoxy-4-formamido-l-arabinose. J. Biol. Chem. 2005, 280:14154-14167.
8. Brown D.A., Tsang J.C. Chemical and electrophoretic changes induced by polymyxin B on outer membrane components from Serratia marcescens. J. Antibiot (Tokyo) 1978, 31:603-609.
9. Campos M.A., Vargas M.A., Regueiro V., Llompart C.M., Alberti S., Bengoechea J.A. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun. 2004, 72:7107-7114.
10. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2008, 52:570-573.
11. Castanheira, M., Sader, H.S., Jones, R.N., Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist.
12. Cezario R.C., Duarte De Morais L., Ferreira J.C., Costa-Pinto R.M., da Costa Darini A.L., Gontijo-Filho P.P. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm Infect. Microbiol. Clin. 2009, 27:269-274.
13. Clausell A., Garcia-Subirats M., Pujol M., Busquets M.A., Rabanal F., Cajal Y. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J. Phys. Chem. B 2007, 111:551-563.
14. Davis S.D., Iannetta A., Wedgwood R.J. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J. Infect. Dis. 1971, 124:610-612.
15. Dobrewski R., Savov E., Bernards A.T., van den Barselaar M., Nordmann P., van den Broek P.J., Dijkshoorn L. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin. Microbiol. Infect. 2006, 12:1135-1137.
16. Eser O.K., Ergin A., Hascelik G. Antimicrobial resistance and existence of metallo-beta-lactamase in Acinetobacter species isolated from adult patients. Mikrobiyol Bul. 2009, 43:383-390.
17. Falagas M.E., Bliziotis I.A., Kasiakou S.K., Samonis G., Athanassopoulou P., Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis. 2005, 5:24.
18. Falagas M.E., Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 2005, 40:1333-1341.
19. Falagas M.E., Kastoris A.C., Karageorgopoulos D.E., Rafailidis P.I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents 2009, 34:111-120.
20. Falagas M.E., Makris G.C., Dimopoulos G., Matthaiou D.K. Heteroresistance: a concern of increasing clinical significance?. Clin. Microbiol. Infect. 2008, 14:101-104.
21. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Mavromanolakis E., Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 2010, 35:240-243.
22. Falagas M.E., Rafailidis P.I., Ioannidou E., Alexiou V.G., Matthaiou D.K., Karageorgopoulos D.E., Kapaskelis A., Nikita D., Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 2010, 35:194-199.
23. Falagas M.E., Rafailidis P.I., Matthaiou D.K., Virtzili S., Nikita D., Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents 2008, 32:450-454.
24. Falagas M.E., Giannopoulou K.P., Kokolakis G.N., Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 2008, 46:1069-1077.
25. Fedler K.A., Biedenbach D.J., Jones R.N. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn. Microbiol. Infect. Dis. 2006, 56:427-436.
26. Fica C.A., Cespedes J.I., Gompertz G.M., Jalon V.M., Sakurada Z.A., Saez L.E. Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli. Rev. Chilena Infectol. 2007, 24:360-367.
27. Fu W., Yang F., Kang X., Zhang X., Li Y., Xia B., Jin C. First structure of the polymyxin resistance proteins. Biochem. Biophys. Res. Commun. 2007, 361:1033-1037.
28. Gales A.C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect. 2006, 12:315-321.
29. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 2001, 39:183-190.
30. Garcia-Penuela E., Aznar E., Alarcon T., Lopez-Brea M. Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs. Hong Kong. Rev. Esp Quimioter. 2006, 19:45-50.
31. Gatzeva-Topalova P.Z., May A.P., Sousa M.C. Crystal structure and mechanism of the Escherichia coli ArnA (PmrI) transformylase domain. An enzyme for lipid A modification with 4-amino-4-deoxy-l-arabinose and polymyxin resistance. Biochemistry 2005, 44:5328-5338.
32. Gatzeva-Topalova P.Z., May A.P., Sousa M.C. Crystal structure of Escherichia coli ArnA (PmrI) decarboxylase domain. A key enzyme for lipid A modification with 4-amino-4-deoxy-L-arabinose and polymyxin resistance. Biochemistry 2004, 43:13370-13379.
33. Gatzeva-Topalova P.Z., May A.P., Sousa M.C. Structure and mechanism of ArnA: conformational change implies ordered dehydrogenase mechanism in key enzyme for polymyxin resistance. Structure 2005, 13:929-942.
34. Gomez-Garces J.L., Aracil B., Gil Y., Burillo A. Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs. J. Chemother. 2009, 21:267-271.
35. Gunn J.S., Miller S.I. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J. Bacteriol. 1996, 178:6857-6864.
36. Hawley J.S., Murray C.K., Griffith M.E., McElmeel M.L., Fulcher L.C., Hospenthal D.R., Jorgensen J.H. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob. Agents Chemother. 2007, 51:376-378.
37. Hawley J.S., Murray C.K., Jorgensen J.H. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 2008, 52:351-352.
38. Hejnar P., Kolar M., Hajek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ. Palacki Olomuc Fac. Med. 1999, 142:73-77.
39. Hernan R.C., Karina B., Gabriela G., Marcela N., Carlos V., Angela F. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 2009, 65:188-191.
40. Hill D., Rose B., Pajkos A., Robinson M., Bye P., Bell S., Elkins M., Thompson B., Macleod C., Aaron S.D., Harbour C. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 2005, 43:5085-5090.
41. Hogardt M., Schmoldt S., Gotzfried M., Adler K., Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 2004, 54:1057-1061.
42. Hussein K., Sprecher H., Mashiach T., Oren I., Kassis I., Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 2009, 30:666-671.
43. Igumbor E., Gwanzura L., Chirara M., Obi C., Muza D. Antibiotic sensitivity and plasmid profiles of Pseudomonas aeruginosa. Cent. Afr. J. Med. 2000, 46:296-300.
44. Iroha E.O., Kesah C.N., Egri-Okwaji M.T., Odugbemi T.O. Bacterial eye infection in neonates, a prospective study in a neonatal unit. West Afr. J. Med. 1998, 17:168-172.
45. Ito-Kagawa M., Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J. Antibiot. (Tokyo) 1980, 33:1551-1555.
46. Jones R.N., Stilwell M.G., Rhomberg P.R., Sader H.S. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn. Microbiol. Infect. Dis. 2009, 65:331-334.
47. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother. 2008, 62:45-55.
48. Kato A., Latifi T., Groisman E.A. Closing the loop: the PmrA/PmrB two-component system negatively controls expression of its posttranscriptional activator PmrD. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4706-4711.
49. Keen E.F., Robinson B.J., Hospenthal D.R., Aldous W.K., Wolf S.E., Chung K.K., Murray C.K. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 2010.
50. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 2008, 62:895-904.
51. Kline T., Trent M.S., Stead C.M., Lee M.S., Sousa M.C., Felise H.B., Nguyen H.V., Miller S.I. Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg. Med. Chem. Lett. 2008, 18:1507-1510.
52. Ko K.S., Suh J.Y., Kwon K.T., Jung S.I., Park K.H., Kang C.I., Chung D.R., Peck K.R., Song J.H. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 2007, 60:1163-1167.
53. Kwa A., Kasiakou S.K., Tam V.H., Falagas M.E. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti Infect. Ther. 2007, 5:811-821.
54. Landman D., Bratu S., Alam M., Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 2005, 55:954-957.
55. Lapteva T.A., Bazhenov L.G., Suiumova A.S., Shabanova N.G. Identification and sensitivity to antimicrobial drugs of enterobacteria isolated from patients with suppurative, inflammatory diseases. Antibiot. Khimioter. 1993, 38:35-40.
56. Lee Y.T., Huang L.Y., Chiang D.H., Chen C.P., Chen T.L., Wang F.D., Fung C.P., Siu L.K., Cho W.L. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int. J. Antimicrob. Agents 2009, 34:580-584.
57. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., Liolios L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2006, 50:2946-2950.
58. Li J., Nation R.L., Owen R.J., Wong S., Spelman D., Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 2007, 45:594-598.
59. MacKenzie F.M., Smith S.V., Milne K.E., Griffiths K., Legge J., Gould I.M. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. J. Cyst. Fibros. 2004, 3:151-157.
60. Manikal V.M., Landman D., Saurina G., Oydna E., Lal H., Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 2000, 31:101-106.
61. Matthaiou D.K., Michalopoulos A., Rafailidis P.I., Karageorgopoulos D.E., Papaioannou V., Ntani G., Samonis G., Falagas M.E. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit. Care Med. 2008, 36:807-811.
62. McPhee J.B., Lewenza S., Hancock R.E. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 2003, 50:205-217.
63. Mendes R.E., Bell J.M., Turnidge J.D., Castanheira M., Jones R.N. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter s in Asia-Pacific nations: report from the SENTRY Surveillance Program. J. Antimicrob. Chemother. 2009, 63:55-59.
64. Mezzatesta M.L., Trovato G., Gona F., Nicolosi V.M., Nicolosi D., Carattoli A., Fadda G., Nicoletti G., Stefani S. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob. 2008, 7:4.
65. Michalopoulos A., Virtzili S., Rafailidis P., Chalevelakis G., Damala M., Falagas M.E. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 2010, 16:184-186.
66. Miftode E., Dorneanu O., Leca D., Teodor A., Mihalache D., Filip O., Luca V. Antimicrobial resistance profile of E. coli and Klebsiella s from urine in the Infectious Diseases Hospital Iasi. Rev. Med. Chir Soc. Med. Nat. Iasi. 2008, 112:478-482.
67. Milne K.E., Gould I.M. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J. Antimicrob. Chemother. 2010, 65:82-90.
68. Moore R.A., Chan L., Hancock R.E. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1984, 26:539-545.
69. Moskowitz S.M., Ernst R.K., Miller S.I. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 2004, 186:575-579.
70. Newton B.A. The properties and mode of action of the polymyxins. Bacteriol. Rev. 1956, 20:14-27.
71. Nicas T.I., Hancock R.E. Alteration of susceptibility to EDTA, polymyxin B and gentamicin in Pseudomonas aeruginosa by divalent cation regulation of outer membrane protein H1. J. Gen. Microbiol. 1983, 129:509-517.
72. Pamp S.J., Gjermansen M., Johansen H.K., Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 2008, 68:223-240.
73. Pitt T.L., Sparrow M., Warner M., Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003, 58:794-796.
74. Punpanich W., Tantichattanon W., Wongwatcharapaiboon S., Treeratweeraphong V. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. J. Med. Assoc. Thai. 2008, 91(Suppl 3):S21-27.
75. Raetz C.R., Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 2002, 71:635-700.
76. Reeves P.R., Hobbs M., Valvano M.A., Skurnik M., Whitfield C., Coplin D., Kido N., Klena J., Maskell D., Raetz C.R., Rick P.D. Bacterial polysaccharide synthesis and gene nomenclature. Trends Microbiol. 1996, 4:495-503.
77. Rose F., Heuer K.U., Sibelius U., Hombach-Klonisch S., Kiss L., Seeger W., Grimminger F. Targeting lipopolysaccharides by the nontoxic polymyxin B nonapeptide sensitizes resistant Escherichia coli to the bactericidal effect of human neutrophils. J. Infect. Dis. 2000, 182:191-199.
78. Roussos N., Karageorgopoulos D.E., Samonis G., Falagas M.E. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 2009, 34:506-515.
79. Schafer J.J., Goff D.A., Stevenson K.B., Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007, 27:980-987.
80. Schindler M., Osborn M.J. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979, 18:4425-4430.
81. Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother. 2002, 49:403-406.
82. Souli M., Kontopidou F.V., Koratzanis E., Antoniadou A., Giannitsioti E., Evangelopoulou P., Kannavaki S., Giamarellou H. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 2006, 50:3166-3169.
83. Sung H., Choi S.J., Yoo S., Kim M.N. In vitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii. Korean J. Lab. Med. 2007, 27:111-117.
84. Tam V.H., Chang K.T., Abdelraouf K., Brioso C.G., Ameka M., McCaskey L.A., Weston J.S., Caeiro J.P., Garey K.W. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2010, 54:1160-1164.
85. Tan T.Y., Hsu L.Y., Koh T.H., Ng L.S., Tee N.W., Krishnan P., Lin R.T., Jureen R. Antibiotic resistance in gram-negative bacilli: a Singapore perspective. Ann. Acad. Med. Singapore 2008, 37:819-825.
86. Tan T.Y., Ng S.Y. The in-vitro activity of colistin in gram-negative bacteria. Singapore Med. J. 2006, 47:621-624.
87. Tognim M.C., Gales A.C., Penteado A.P., Silbert S., Sader H.S. Dissemination of IMP-1 metallo- beta -lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect. Control Hosp. Epidemiol. 2006, 27:742-747.
88. Tsubery H., Ofek I., Cohen S., Fridkin M. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria. J. Med. Chem. 2000, 43:3085-3092.
89. Varaiya A., Kulkarni M., Bhalekar P., Dogra J. Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients. Indian J. Pathol. Microbiol. 2008, 51:200-203.
90. Walkty A., Decorby M., Nichol K., Mulvey M.R., Hoban D., Zhanel G. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn. Microbiol. Infect. Dis. 2008, 61:217-221.
91. Warren H.S., Kania S.A., Siber G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 1985, 28:107-112.
92. Winfield M.D., Groisman E.A. Phenotypic differences between Salmonella and Escherichia coli resulting from the disparate regulation of homologous genes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17162-17167.
93. Winfield M.D., Latifi T., Groisman E.A. Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis. J. Biol. Chem. 2005, 280:14765-14772.
94. Yan A., Guan Z., Raetz C.R. An undecaprenyl phosphate-aminoarabinose flippase required for polymyxin resistance in Escherichia coli. J. Biol. Chem. 2007, 282:36077-36089.
95. Yang Q.W., Xu Y.C., Chen M.J., Hu Y.J., Ni Y.X., Sun J.Y., Yu Y.S., Kong H.S., He L., Wu W.Y., Ye H.F., Yang Y.M., Zhu L.N., Guo S.H., Ji P., Zhu Z.H., Ren J.K., Zhang L.X., Sun Z.Y., Zhu X.H., Tong M.Q., Zhao W.S., Mei Y.N., Liu Y., Zhang Z.J., Duan Q., Li D., Liu P.P., Wang J., Han L.X., Wang H., Xie X.L. Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005. Zhonghua Yi Xue Za Zhi 2007, 87:2753-2758.
96. Yau W., Owen R.J., Poudyal A., Bell J.M., Turnidge J.D., Yu H.H., Nation R.L., Li J. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 2009, 58:138-144.
97. Zhanel G.G., Karlowsky J.A., Rubinstein E., Hoban D.J. Tigecycline: a novel glycylcycline antibiotic. Expert Rev. Anti Infect. Ther. 2006, 4:9-25.